Kyverna Therapeutics, Inc., clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. The company's lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, lupus nephritis, and rapid whole blood process. It is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing, as well as KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California. Show more
Location: 5980 Horton Street, Emeryville, CA, 94608, United States | Website: https://kyvernatx.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
160.9M
52 Wk Range
$1.78 - $7.85
Previous Close
$3.72
Open
$3.72
Volume
225,702
Day Range
$3.56 - $3.78
Enterprise Value
-45.32M
Cash
211.7M
Avg Qtr Burn
-35.35M
Insider Ownership
12.03%
Institutional Own.
62.34%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
KYV-101 Details Lupus nephritis | Phase 1 Update |